Market Maven’s “ISO” Spinoff Pitch: A Real Thesis Wrapped in a $2,500 No-Refund Price Tag

The Hook

The pitch opens by telling you that the party is over, and that the real money was never at the party to begin with. Gabe Marshank’s “Market Maven” letter, published under Stansberry Research, frames the end of 2026’s IPO wave as the setup for a follow-on trade he calls the “IPOcalypse aftershock.” His coinage is “ISO,” short for “investable spinoff,” and the entire promo hangs on the idea that while ordinary investors were distracted by splashy public listings, the companies being carved out of bigger parents are where the quieter, larger gains will show up. For the specifics, our “Spinout Company: What You Need to Know” article is worth a read.

The urgency mechanism here is a contrast, not a countdown clock. Marshank points at the record-breaking SpaceX IPO and other marquee listings and argues they exist to enrich insiders and bankers, not the retail buyer. “Big public events like the record-breaking SpaceX IPO… exist to make money for Wall Street, not individual investors,” the promo says. “That’s why IPOs are a losing bet.” The fix, he argues, is to buy the spinoffs nobody is watching instead of the IPOs everyone is.

It is a genuinely smart framing, because it flips the most hyped event of the year into a reason to look somewhere else. The question the rest of this teardown has to answer is whether the specific package being sold, at its specific price, lives up to the cleverness of the hook.

The Big Claim

There are two headline numbers in play. The first is the return: “Wall Street’s wild 2026 IPO spree is ending. But your next opportunity could be more than 8X bigger…” The “more than 8X” is never benchmarked against anything specific, but the implication is clear, that the spinoff wave offers something dramatically larger than whatever the IPO wave handed out.

The second is the credential. The promo says of Marshank that “he’s already banked more than $100,000,000 from this hidden aftershock trade at Manhattan’s top hedge funds.” That line is doing a lot of work, because it is the main evidence offered that the presenter actually knows how to capture the spinoff trade rather than just talk about it.

Those claims are packaged into two special reports: “Ultimate ISO” and “Our Next 9-Figure Power Deal.” The second title gives away the promise plainly: a nine-figure, meaning $100 million-plus, opportunity. Two tickers are teased in the free materials: Versigent (VGNT) at $44.16 and Solstice Advanced Materials (SOLS) at $60.23. Our “Stock Spinoff: What You Need to Know” article covers the details.

The Mechanism

The underlying mechanism is legitimate and worth explaining, because it is the strongest part of the pitch. A spinoff is what happens when a larger parent company separates one of its business units into a standalone, publicly traded company, usually by distributing shares of the new entity to the parent’s existing shareholders.

Spinoffs have a well-documented tendency to get orphaned early on. When a unit is carved out, the shareholders of the parent often receive the new shares but have no particular reason to want them, since they bought the parent for a different reason. Index and mutual funds that hold the parent may be forced to sell the spinoff because it does not fit their mandate. The result is a period of indiscriminate selling in the first months after separation, which can leave a perfectly good business trading at a discount to its intrinsic value. On top of that, a newly independent management team, finally unshackled from the parent’s capital allocation, often runs the business better with a cleaner focus on its own operations.

That is the “ISO” idea in plain terms. Marshank’s framing is that 2026 produced a wave of IPOs, and now, as those markets cool, the spinoffs coming behind them represent the “aftershock.” It is a coherent story, and it is one with real academic and market history behind it.

The two teased names are where the pitch gets harder to pin down. Versigent (VGNT) is teased at $44.16 and trades near a $2.95 billion market cap. Solstice Advanced Materials (SOLS) is teased at $60.23 and carries a roughly $10 billion market cap. Beyond the tickers, the tease prices, and those valuations, the free materials do not hand you much in the way of independently verifiable business detail, which is worth keeping in mind. You are being asked to subscribe in order to find out exactly why these two names, rather than any other spinoff, are the ones to own.

The Real Pick

Current prices are as of the October 27, 2026 close, from Polygon.

Versigent’s market cap is about $2.95 billion at these prices. Solstice Advanced Materials sits near $10 billion. Neither name has moved dramatically since the tease: one is down a little under 6%, the other up a little over 4.5%. There is no runaway winner or collapse here yet, which itself is information. The “more than 8X bigger” opportunity is, so far, showing up as a roughly flat pair of picks.

Does the Math Check Out

Let us separate two things that the promo deliberately blurs: the spinoff wave is real, and this specific letter’s ISO picks at $2,500 a year are a different question entirely.

On the first point, the promo is standing on solid ground. Academic work on spinoffs going back decades has generally found that spinoffs, and the parent companies that shed them, tend to outperform the broader market in the first years after separation. The orphan-effect selling I described above is a real, measurable phenomenon, not a marketing invention. So when Marshank says the spinoff wave deserves attention, he is repeating a conclusion that has survived a lot of scrutiny. An investor who ignores spinoffs is ignoring one of the few areas where small investors can genuinely have an informational edge, since the selling is mechanical rather than informed.

The problem is that “spinoffs tend to do well” does not automatically become “these two specific picks are worth $2,500 a year.” And that is where the math gets uncomfortable.

First, the track record. Marshank’s splashy launch pick, Grail (GRAL), did genuinely well, and it is fair to give him credit for that. But StockGumshoe’s review of his work notes that his five other teased names are all down between 15% and 65%. That is a one-for-six batting average on the names the marketing has surfaced so far. A thesis can be sound while the execution is mixed, but a mixed execution record matters a lot when the admission price is this high.

Second, the pricing and refund asymmetry. This letter lists at $10,000, is promoted at $2,500 a year, and offers no refunds. The “satisfaction guaranteed” language turns out to mean that within 30 days you can swap to a different Stansberry service, not that you can get your money back. So your $2,500 is not recoverable cash if the picks disappoint; it is store credit at the same seller. That is a meaningful asymmetry, because it means the downside is locked in from day one regardless of how the picks perform.

Third, the credential is unverifiable. The claim that Marshank “banked more than $100,000,000” from this trade “at Manhattan’s top hedge funds” cannot be checked. It may be true, but there is no public record you can point to, and that is precisely the kind of line that a high-priced subscription leans on when the picks themselves have not yet delivered.

Fourth, the broader cost evidence works against the pitch. StockGumshoe’s own twenty-year finding across the industry is that $1,000-plus upgrade letters do not, on average, outperform the $39 to $199 entry letters. The expensive tier is usually a pricing structure, not a performance tier. This letter is the priciest one StockGumshoe tracks, which means it is the clearest test of that pattern, and the pattern says the premium does not buy you better results.

Finally, the two names in front of you right now are roughly flat. One is down 5.84%, the other up 4.55%. If the “more than 8X bigger” aftershock trade is already underway, these two teasers are not yet showing it. That does not mean they will not work, but it does mean the urgency in the pitch is not being validated by the prices it teases.

The honest summary is that you can buy the entire legitimate thesis, that spinoffs outperform and IPOs are a bad deal for individuals, for the price of a library card and a little patience. The specific question of whether Versigent and Solstice Advanced Materials are the right spinoffs is something the promo will only answer after you pay $2,500 with no refund.

The Verdict

Skip the subscription, keep the thesis. The spinoff wave is a real, academically supported opportunity, and Marshank deserves credit for explaining it clearly and for a genuinely strong launch pick in Grail. But you do not need to pay $2,500 a year, with no refunds, to act on the idea that spinoffs outperform IPOs. That idea is freely available, and it is the strongest thing in the whole pitch. The specific picks being sold have not yet validated the “more than 8X” promise, the credential backing the presenter is unverifiable, the recent teased track record is mostly down, and the industry-wide evidence says expensive upgrade letters do not beat cheap entry letters. If you want to pursue the aftershock trade, study spinoffs yourself, or buy a far cheaper letter, and keep your $2,500. There is no refund waiting for you if the “Ultimate ISO” turns out to be ordinary.

What They Got Right

• The spinoff thesis itself is grounded in real, long-standing academic evidence that spinoffs tend to outperform in the years after separation, driven by mechanical index-fund selling and newly focused management.
• The observation that marquee IPOs are structured to benefit insiders, bankers, and early institutional buyers more than retail investors is true, and flipping the reader’s attention from IPOs to spinoffs is a genuinely useful reframing.
• Marshank’s launch pick, Grail (GRAL), actually worked out well, so the presenter has at least one demonstrated winner rather than an entirely unproven record.
• Naming a real, researchable category like spinoffs, rather than a vague “secret technology,” points readers toward a strategy they can actually learn and execute on their own.
• The mechanism explanation, orphaned shares plus focused management, is honest and educational rather than mystical, which is more than many promos offer.

What They Got Wrong

• The “$100,000,000 banked at Manhattan’s top hedge funds” credential is unverifiable, and it carries most of the weight of the presenter’s authority without any public record to back it up.
• The pricing and refund structure is asymmetric: $10,000 list, $2,500 promoted, no refunds, and “satisfaction guaranteed” means only a swap to another Stansberry product within 30 days, not a return of your money.
• The teased track record is mostly negative, with five other names down between 15% and 65%, which undercuts the “more than 8X bigger” framing even while Grail succeeded.
• The two current teasers are roughly flat, one down 5.84% and one up 4.55%, so the promised aftershock urgency is not yet showing up in the prices being advertised.
• The “more than 8X bigger” claim is vague and unbenchmarked, an emotional multiplier rather than a specific, checkable projection, and the $10,000 “list price” functions as an anchor to make $2,500 look like a bargain.

Compliance Disclaimer

This is not financial advice. NewsletterVetter has no position in any stock mentioned.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice.